董事介绍
注:董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin Chen | 男 | Chairman of the Board and Chief Executive Officer | 44 | 未披露 | 未持股 | 2023-01-24 |
| Gang Li | 男 | Director | 50 | 未披露 | 未持股 | 2023-01-24 |
| Yan Michael Li | 男 | Director | 50 | 未披露 | 未持股 | 2023-01-24 |
| Jintao Zheng | 男 | Director | 46 | 未披露 | 未持股 | 2023-01-24 |
| Bob Ai | 男 | Chief Financial Officer and Director | 58 | 未披露 | 未持股 | 2023-01-24 |
高管介绍
注:高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Kevin Chen | 男 | Chairman of the Board and Chief Executive Officer | 44 | 未披露 | 未持股 | 2023-01-24 |
| Bob Ai | 男 | Chief Financial Officer and Director | 58 | 未披露 | 未持股 | 2023-01-24 |
董事简历
中英对照 |  中文 |  英文- Kevin Chen
-
陈凯文自2020年9月以来一直担任我们的董事会主席兼首席执行官。陈天桥一直担任Horizon Financial的首席投资官和首席经济学家,Horizon Financial是一家总部位于纽约的投资管理公司,为全球金融机构和个人提供跨境投资解决方案,自2018年5月起,他负责建议客户在美国投资医疗保健设施。自2021年11月以来,陈先生一直是Infint Acquisition Corporation的董事会成员,NYSE:IFIN.U是一家特殊目的收购公司,于2021年11月23日完成了首次公开募股。自2019年2月以来,陈先生还一直担任Horizon Global Access Fund(开曼)的董事会成员,该基金是美国领先的Heathcare REIT旗舰医疗保健Properties Fund的独立投资组合。此前,Kevin曾担任Credit Agricole/Amundi Asset Management的高级投资组合经理,直到2015年10月,也曾担任摩根士丹利的资产配置董事(从2004年8月到2008年8月),以及中国开发银行的经理(从1998年9月到2000年8月)。Kevin是中国绝对回报投资管理协会联席Founder兼副主席。Kevin也是哈佛大学、福特汉姆大学、佩斯大学和IESE商学院的特邀演讲人。他是纽约大学全球事务理学硕士私人部门集中项目的前兼职咨询委员会成员和前临时负责人,自2012年以来一直是该公司的兼职教授。他是纽约经济俱乐部的成员,纽约金融论坛的联合主席,外交政策协会的研究员,布雷顿森林委员会的成员,科罗拉多大学丹佛商学院摩根大通大宗商品中心全球大宗商品应用研究文摘编辑顾问委员会成员。Kevin于2005年在瑞士洛桑大学金融资产管理工程中心获得金融学博士学位,于2001年在荷兰蒂尔堡大学经济研究中心获得金融学硕士学位,并于1998年在中国人民大学获得经济学学士学位。
Kevin Chen,has been Edoc Acquisition Corp. Chairman of the board of directors and Chief Executive Officer since September 2020. Mr. Chen has been serving as Chief Investment Officer and Chief Economist of Horizon Financial, a New York based investment management company that offers cross-border investment solutions to global financial institutions and individuals, since May 2018, where he is responsible for advising clients in investing healthcare facilities in the United States. Since November 2021, Mr. Chen has been a board member of InFinT Acquisition Corporation (NYSE: IFIN.U), a special purpose acquisition company that completed its initial public offering in November 23, 2021. Mr. Chen has also been serving as a board member of Horizon Global Access Fund (Cayman), a segregate portfolio of Flagship Healthcare Properties Fund, a leading U.S. Healthcare REIT, since February 2019. Previously Kevin served as a senior portfolio manager of Credit Agricole/Amundi Asset Management until October 2015, a director of Asset Allocation of Morgan Stanley from August 2004 to August 2008, and a manager of China Development Bank from September 1998 to August 2000. Kevin is Co-Founder and Vice-Chairman of the Absolute Return Investment Management Association of China. Kevin has also been a guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. He is a former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program of Master of Science in Global Affairs, New York University, and has been an adjunct professor there since 2012. He is a Member of the Economic Club of New York, Fellow of the Foreign Policy Association, Member of the Bretton Woods Committee, Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Kevin obtained his PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland in 2005, Master's degree in Finance, Center for Economic Research, Tilburg University in the Netherland in 2001, and B.A. degree in Economics from the Renmin University of China in China in 1998. - 陈凯文自2020年9月以来一直担任我们的董事会主席兼首席执行官。陈天桥一直担任Horizon Financial的首席投资官和首席经济学家,Horizon Financial是一家总部位于纽约的投资管理公司,为全球金融机构和个人提供跨境投资解决方案,自2018年5月起,他负责建议客户在美国投资医疗保健设施。自2021年11月以来,陈先生一直是Infint Acquisition Corporation的董事会成员,NYSE:IFIN.U是一家特殊目的收购公司,于2021年11月23日完成了首次公开募股。自2019年2月以来,陈先生还一直担任Horizon Global Access Fund(开曼)的董事会成员,该基金是美国领先的Heathcare REIT旗舰医疗保健Properties Fund的独立投资组合。此前,Kevin曾担任Credit Agricole/Amundi Asset Management的高级投资组合经理,直到2015年10月,也曾担任摩根士丹利的资产配置董事(从2004年8月到2008年8月),以及中国开发银行的经理(从1998年9月到2000年8月)。Kevin是中国绝对回报投资管理协会联席Founder兼副主席。Kevin也是哈佛大学、福特汉姆大学、佩斯大学和IESE商学院的特邀演讲人。他是纽约大学全球事务理学硕士私人部门集中项目的前兼职咨询委员会成员和前临时负责人,自2012年以来一直是该公司的兼职教授。他是纽约经济俱乐部的成员,纽约金融论坛的联合主席,外交政策协会的研究员,布雷顿森林委员会的成员,科罗拉多大学丹佛商学院摩根大通大宗商品中心全球大宗商品应用研究文摘编辑顾问委员会成员。Kevin于2005年在瑞士洛桑大学金融资产管理工程中心获得金融学博士学位,于2001年在荷兰蒂尔堡大学经济研究中心获得金融学硕士学位,并于1998年在中国人民大学获得经济学学士学位。
- Kevin Chen,has been Edoc Acquisition Corp. Chairman of the board of directors and Chief Executive Officer since September 2020. Mr. Chen has been serving as Chief Investment Officer and Chief Economist of Horizon Financial, a New York based investment management company that offers cross-border investment solutions to global financial institutions and individuals, since May 2018, where he is responsible for advising clients in investing healthcare facilities in the United States. Since November 2021, Mr. Chen has been a board member of InFinT Acquisition Corporation (NYSE: IFIN.U), a special purpose acquisition company that completed its initial public offering in November 23, 2021. Mr. Chen has also been serving as a board member of Horizon Global Access Fund (Cayman), a segregate portfolio of Flagship Healthcare Properties Fund, a leading U.S. Healthcare REIT, since February 2019. Previously Kevin served as a senior portfolio manager of Credit Agricole/Amundi Asset Management until October 2015, a director of Asset Allocation of Morgan Stanley from August 2004 to August 2008, and a manager of China Development Bank from September 1998 to August 2000. Kevin is Co-Founder and Vice-Chairman of the Absolute Return Investment Management Association of China. Kevin has also been a guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. He is a former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program of Master of Science in Global Affairs, New York University, and has been an adjunct professor there since 2012. He is a Member of the Economic Club of New York, Fellow of the Foreign Policy Association, Member of the Bretton Woods Committee, Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Kevin obtained his PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland in 2005, Master's degree in Finance, Center for Economic Research, Tilburg University in the Netherland in 2001, and B.A. degree in Economics from the Renmin University of China in China in 1998.
- Gang Li
-
李刚自2020年11月起担任董事。李博士自2012年7月以来一直是综合脊柱和运动中心的医师合作伙伴和教育总监,该中心是硅谷最大的疼痛管理和运动医学中心之一,提供全面和多学科的疼痛管理服务。他也一直担任Stanford University Pain Management Center的兼职临床教师(2013年7月以来),在那里他教斯坦福大学的居民和研究员关于前沿的疼痛管理知识和技术。他在著名的同行评审的国际医学期刊上发表了15篇论文,在国家和国际会议上发表了13篇摘要,主题从疼痛管理,再生医学,医疗保健风险分层到衰老,肥胖和糖尿病的分子机制和药理学干预。李博士还一直担任iHealth Frontier的首席医疗官,这是一家创新的初创公司,致力于通过医疗保健分析和基础设施软件为ACOS负责的护理组织(Medicare和Commercial),IPAS(独立医师协会)和商业付款人改善医疗保健结果,同时降低总体成本。李博士是一名获得董事会认证的哈佛大学培训的麻醉师和斯坦福大学培训的介入疼痛医学专家。他于2010年完成了麻省总医院/哈佛医学院的麻醉学住院医师,并于2011年完成了斯坦福大学医学院的多学科疼痛管理研究金。在专业培训之前,他于1997年毕业于中国北京协和医学院,获得医学学位。李博士于2003年在佛罗里达大学获得衰老和代谢紊乱的神经药理学博士学位。
Gang Li,has served as a Director since November 2020. Dr. Li has been a physician partner and Education Director at the Comprehensive Spine and Sports Center since July 2012, one of the largest pain management and sports medicine center in Silicon Valley, which provides comprehensive and multidisciplinary pain management services. He has also been serving as an adjunct clinical faculty at Stanford University Pain Management Center since July 2013, where he teaches Stanford residents and fellows on the cutting-edge pain management knowledge and techniques. He has published 15 papers in prestigious peer-reviewed international medical journals and 13 abstracts in national and international conferences on topics ranging from pain management, regenerate medicine, healthcare risk stratification to molecular mechanisms and pharmacological intervention for aging, obesity and diabetes. Dr. Li has also been serving as Chief Medical Officer of iHealth Frontier, an innovative start-up focusing on improving the healthcare outcome with healthcare analytics and infrastructure software for ACOs (Accountable Care Organizations) (Medicare and commercial), IPAs (Independent Physician Associations) and commercial payers, while reducing the overall costs. Dr. Li is a board certified, Harvard-trained anesthesiologist and a Stanford-trained interventional Pain Medicine specialist. He completed his anesthesiology residency from Massachusetts General Hospital/Harvard Medical School in 2010 and his fellowship in Multidisciplinary Pain Management at Stanford University School of Medicine in 2011. Prior to the specialty training, he graduated from Peking Union Medical College in China in 1997 with a medical degree. Dr. Li received his PhD degree in neuropharmacology of Aging and metabolic disorders from the University of Florida in 2003. - 李刚自2020年11月起担任董事。李博士自2012年7月以来一直是综合脊柱和运动中心的医师合作伙伴和教育总监,该中心是硅谷最大的疼痛管理和运动医学中心之一,提供全面和多学科的疼痛管理服务。他也一直担任Stanford University Pain Management Center的兼职临床教师(2013年7月以来),在那里他教斯坦福大学的居民和研究员关于前沿的疼痛管理知识和技术。他在著名的同行评审的国际医学期刊上发表了15篇论文,在国家和国际会议上发表了13篇摘要,主题从疼痛管理,再生医学,医疗保健风险分层到衰老,肥胖和糖尿病的分子机制和药理学干预。李博士还一直担任iHealth Frontier的首席医疗官,这是一家创新的初创公司,致力于通过医疗保健分析和基础设施软件为ACOS负责的护理组织(Medicare和Commercial),IPAS(独立医师协会)和商业付款人改善医疗保健结果,同时降低总体成本。李博士是一名获得董事会认证的哈佛大学培训的麻醉师和斯坦福大学培训的介入疼痛医学专家。他于2010年完成了麻省总医院/哈佛医学院的麻醉学住院医师,并于2011年完成了斯坦福大学医学院的多学科疼痛管理研究金。在专业培训之前,他于1997年毕业于中国北京协和医学院,获得医学学位。李博士于2003年在佛罗里达大学获得衰老和代谢紊乱的神经药理学博士学位。
- Gang Li,has served as a Director since November 2020. Dr. Li has been a physician partner and Education Director at the Comprehensive Spine and Sports Center since July 2012, one of the largest pain management and sports medicine center in Silicon Valley, which provides comprehensive and multidisciplinary pain management services. He has also been serving as an adjunct clinical faculty at Stanford University Pain Management Center since July 2013, where he teaches Stanford residents and fellows on the cutting-edge pain management knowledge and techniques. He has published 15 papers in prestigious peer-reviewed international medical journals and 13 abstracts in national and international conferences on topics ranging from pain management, regenerate medicine, healthcare risk stratification to molecular mechanisms and pharmacological intervention for aging, obesity and diabetes. Dr. Li has also been serving as Chief Medical Officer of iHealth Frontier, an innovative start-up focusing on improving the healthcare outcome with healthcare analytics and infrastructure software for ACOs (Accountable Care Organizations) (Medicare and commercial), IPAs (Independent Physician Associations) and commercial payers, while reducing the overall costs. Dr. Li is a board certified, Harvard-trained anesthesiologist and a Stanford-trained interventional Pain Medicine specialist. He completed his anesthesiology residency from Massachusetts General Hospital/Harvard Medical School in 2010 and his fellowship in Multidisciplinary Pain Management at Stanford University School of Medicine in 2011. Prior to the specialty training, he graduated from Peking Union Medical College in China in 1997 with a medical degree. Dr. Li received his PhD degree in neuropharmacology of Aging and metabolic disorders from the University of Florida in 2003.
- Yan Michael Li
-
Yan Michael Li,自2022年10月起担任董事。李先生是一名神经外科医生,也是微创脑和脊柱研究所(MIBSI)的主任,他自2020年7月以来一直在该研究所工作。李先生自2014年7月起担任犹他州医学博士安德森癌症中心的临床助理教授,并自2021年3月起担任SUNY北部医科大学的临床助理教授。李医生擅长治疗复杂的脊柱疾病以及脑和脊柱肿瘤。自2021年8月起,他担任ExoNanoRNA,LLC的首席执行官和董事会董事,该公司是一家平台生物技术公司,开发一种新型的基于RNA纳米技术的癌症和疫苗疗法。自2016年12月起,他担任AIH LLC的Founder兼总裁,该公司是一家基于智能可穿戴设备的Spine和Neuro AI医疗保健和管理公司。李先生在北京协和医学院获得医学学位,并在纽约州立大学上州医科大学、达纳-法伯癌症研究所和哈佛医学院波士顿儿童医院接受住院和研究金培训。李博士在休斯敦的德克萨斯大学安德森癌症中心完成了神经外科肿瘤学研究金培训,重点是复杂的脊柱肿瘤手术。我们认为,由于李先生在医疗保健和医疗保健提供者领域拥有丰富的运营、投资和董事会经验,他完全有资格担任董事。
Yan Michael Li,has served as a Director since October 2022. Mr. Li is a neurosurgeon and director of Minimally Invasive Brain and Spine Institute (MIBSI), where he has been since July 2020. Since July 2014, Mr. Li has served as Clinical Assistant Professor at UT MD Anderson Cancer Center and has served as Clinical Assistant Professor at SUNY Upstate Medical University since March 2021. Dr. Li specializes in treating complex spine disorders and brain and spine tumors. Since August 2021, he has served as Chief Executive Officer and board director of ExoNanoRNA, LLC, a platform biotechnology company developing a new class of RNA nanotechnology-based therapeutics for cancer, and vaccine. Since December 2016, he has served as the Founder and President of AIH LLC, a smart wearable devices-based Spine and Neuro AI Healthcare and Management Company. Mr. Li received his medical degree from Peking Union Medical College and underwent resident and fellowship training at the State University of New York Upstate Medical University and the Dana-Farber Cancer Institute and Boston Children Hospital at Harvard Medical School. Dr. Li completed neurosurgical oncology fellowship training at The University of Texas MD Anderson Cancer Center in Houston focusing on complex spine tumor surgery. - Yan Michael Li,自2022年10月起担任董事。李先生是一名神经外科医生,也是微创脑和脊柱研究所(MIBSI)的主任,他自2020年7月以来一直在该研究所工作。李先生自2014年7月起担任犹他州医学博士安德森癌症中心的临床助理教授,并自2021年3月起担任SUNY北部医科大学的临床助理教授。李医生擅长治疗复杂的脊柱疾病以及脑和脊柱肿瘤。自2021年8月起,他担任ExoNanoRNA,LLC的首席执行官和董事会董事,该公司是一家平台生物技术公司,开发一种新型的基于RNA纳米技术的癌症和疫苗疗法。自2016年12月起,他担任AIH LLC的Founder兼总裁,该公司是一家基于智能可穿戴设备的Spine和Neuro AI医疗保健和管理公司。李先生在北京协和医学院获得医学学位,并在纽约州立大学上州医科大学、达纳-法伯癌症研究所和哈佛医学院波士顿儿童医院接受住院和研究金培训。李博士在休斯敦的德克萨斯大学安德森癌症中心完成了神经外科肿瘤学研究金培训,重点是复杂的脊柱肿瘤手术。我们认为,由于李先生在医疗保健和医疗保健提供者领域拥有丰富的运营、投资和董事会经验,他完全有资格担任董事。
- Yan Michael Li,has served as a Director since October 2022. Mr. Li is a neurosurgeon and director of Minimally Invasive Brain and Spine Institute (MIBSI), where he has been since July 2020. Since July 2014, Mr. Li has served as Clinical Assistant Professor at UT MD Anderson Cancer Center and has served as Clinical Assistant Professor at SUNY Upstate Medical University since March 2021. Dr. Li specializes in treating complex spine disorders and brain and spine tumors. Since August 2021, he has served as Chief Executive Officer and board director of ExoNanoRNA, LLC, a platform biotechnology company developing a new class of RNA nanotechnology-based therapeutics for cancer, and vaccine. Since December 2016, he has served as the Founder and President of AIH LLC, a smart wearable devices-based Spine and Neuro AI Healthcare and Management Company. Mr. Li received his medical degree from Peking Union Medical College and underwent resident and fellowship training at the State University of New York Upstate Medical University and the Dana-Farber Cancer Institute and Boston Children Hospital at Harvard Medical School. Dr. Li completed neurosurgical oncology fellowship training at The University of Texas MD Anderson Cancer Center in Houston focusing on complex spine tumor surgery.
- Jintao Zheng
-
郑金涛,自2022年10月起担任董事。郑先生自2002年7月起担任达美国际公司的Founder兼总裁。郑先生担任总裁,负责业务发展。郑先生自2016年起担任投资公司Brilliant Investment LLC的Founder兼总裁。自2004年起,他担任Trinity Distribution Inc.的Founder兼总裁,负责监督预算、员工和执行人员,并评估公司的成功与否。从2003年1月至2010年1月,郑先生担任山东三陶食品有限公司的首席执行官。郑先生在国际商业物流和供应链管理行业拥有超过20年的业务主管经验。郑先生毕业于休斯顿大学,获得工商管理学士学位和会计学硕士学位。我们认为,由于郑先生的财务和会计专长以及在业务运营和投资方面的经验,他完全有资格担任董事。
Jintao Zheng,has served as a Director since October 2022. Mr. Zheng is the Founder and President of Delta International Inc., where he has been since July 2002. Mr. Zheng serves as the President, where he is responsible for business development. Since 2016, Mr. Zheng has served as the Founder and President of Brilliant Investment LLC, an investment firm. Since 2004, he has served as the Founder and President of Trinity Distribution Inc., where he was responsible for overseeing budgets, staff, and executives and evaluating the success of the company. From January 2003 to January 2010, Mr. Zheng served as the Chief Executive Officer of Shandong Santao Foods Co., Ltd. Mr. Zheng has over 20 years of experience as a business executive in the International Business Logistic and Supply Chain Management industry. Mr. Zheng graduated from University of Houston with a B.S. in Business Administration and a M.S. in Accountancy. - 郑金涛,自2022年10月起担任董事。郑先生自2002年7月起担任达美国际公司的Founder兼总裁。郑先生担任总裁,负责业务发展。郑先生自2016年起担任投资公司Brilliant Investment LLC的Founder兼总裁。自2004年起,他担任Trinity Distribution Inc.的Founder兼总裁,负责监督预算、员工和执行人员,并评估公司的成功与否。从2003年1月至2010年1月,郑先生担任山东三陶食品有限公司的首席执行官。郑先生在国际商业物流和供应链管理行业拥有超过20年的业务主管经验。郑先生毕业于休斯顿大学,获得工商管理学士学位和会计学硕士学位。我们认为,由于郑先生的财务和会计专长以及在业务运营和投资方面的经验,他完全有资格担任董事。
- Jintao Zheng,has served as a Director since October 2022. Mr. Zheng is the Founder and President of Delta International Inc., where he has been since July 2002. Mr. Zheng serves as the President, where he is responsible for business development. Since 2016, Mr. Zheng has served as the Founder and President of Brilliant Investment LLC, an investment firm. Since 2004, he has served as the Founder and President of Trinity Distribution Inc., where he was responsible for overseeing budgets, staff, and executives and evaluating the success of the company. From January 2003 to January 2010, Mr. Zheng served as the Chief Executive Officer of Shandong Santao Foods Co., Ltd. Mr. Zheng has over 20 years of experience as a business executive in the International Business Logistic and Supply Chain Management industry. Mr. Zheng graduated from University of Houston with a B.S. in Business Administration and a M.S. in Accountancy.
- Bob Ai
-
Bob Ai,2011年2月,被任命为首席财务官办公室成员。他有着10年多的华尔街工作经验,以及15年的科学研究学术经验。最近的任职是在2007-2011,担任Merlin Nexus的合伙人,负责投资决策和分析和评估,这是投资于生命科学公司的私募股权公司。2006-2007,他担任经纪交易商Wall Street Access的副总裁,负责行业研究;2004-2005,担任资产管理公司Bennett Lawrence的高级股票分析师;2001-2004,担任资产管理公司Merlin Biomed的分析师。进入金融行业之前,他在University of Pennsylvania担任了7年的研究助理、博士后研究学者。2001年,他在 Penn State University 获得工商管理硕士学位;1992年,在该校获得分子与细胞生物博士学位。
Bob Ai,has served as a Director since November 2020 and as Edoc Acquisition Corp. Chief Financial Oficcer since October 2022. Mr. Ai has served as a managing partner of Goby Global LLC, which provides financial communications, cross-border licensing, and other strategic advisory services since January 2022. From September 2016 to December 2021, Mr. Ai served as managing director of Solebury Trout, a strategic communications firm. Prior to this, Mr. Ai served as a Managing Director and a Senior Biotech Analyst of WallachBeth Capital, a boutique broker-dealer. From February 2011 to June 2012, he served as Chief Financial Officer of Aoxing Pharmaceutical, an NYSE-listed Chinese specialty pharmaceutical company at the time. He also served as a Principal of Merlin Nexus, a crossover life science private equity firm, from March 2007 to January 2011, and served as a Senior Equity Analyst of Bennett Lawrence and Merlin Biomed Group, both asset management firms. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses, which are currently inactive. Mr. Ai received his Ph.D. and MBA degrees from Penn State University in 1992 and 2001, respectively, and did postdoctoral training at the University of Pennsylvania. - Bob Ai,2011年2月,被任命为首席财务官办公室成员。他有着10年多的华尔街工作经验,以及15年的科学研究学术经验。最近的任职是在2007-2011,担任Merlin Nexus的合伙人,负责投资决策和分析和评估,这是投资于生命科学公司的私募股权公司。2006-2007,他担任经纪交易商Wall Street Access的副总裁,负责行业研究;2004-2005,担任资产管理公司Bennett Lawrence的高级股票分析师;2001-2004,担任资产管理公司Merlin Biomed的分析师。进入金融行业之前,他在University of Pennsylvania担任了7年的研究助理、博士后研究学者。2001年,他在 Penn State University 获得工商管理硕士学位;1992年,在该校获得分子与细胞生物博士学位。
- Bob Ai,has served as a Director since November 2020 and as Edoc Acquisition Corp. Chief Financial Oficcer since October 2022. Mr. Ai has served as a managing partner of Goby Global LLC, which provides financial communications, cross-border licensing, and other strategic advisory services since January 2022. From September 2016 to December 2021, Mr. Ai served as managing director of Solebury Trout, a strategic communications firm. Prior to this, Mr. Ai served as a Managing Director and a Senior Biotech Analyst of WallachBeth Capital, a boutique broker-dealer. From February 2011 to June 2012, he served as Chief Financial Officer of Aoxing Pharmaceutical, an NYSE-listed Chinese specialty pharmaceutical company at the time. He also served as a Principal of Merlin Nexus, a crossover life science private equity firm, from March 2007 to January 2011, and served as a Senior Equity Analyst of Bennett Lawrence and Merlin Biomed Group, both asset management firms. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses, which are currently inactive. Mr. Ai received his Ph.D. and MBA degrees from Penn State University in 1992 and 2001, respectively, and did postdoctoral training at the University of Pennsylvania.
高管简历
中英对照 |  中文 |  英文- Kevin Chen
陈凯文自2020年9月以来一直担任我们的董事会主席兼首席执行官。陈天桥一直担任Horizon Financial的首席投资官和首席经济学家,Horizon Financial是一家总部位于纽约的投资管理公司,为全球金融机构和个人提供跨境投资解决方案,自2018年5月起,他负责建议客户在美国投资医疗保健设施。自2021年11月以来,陈先生一直是Infint Acquisition Corporation的董事会成员,NYSE:IFIN.U是一家特殊目的收购公司,于2021年11月23日完成了首次公开募股。自2019年2月以来,陈先生还一直担任Horizon Global Access Fund(开曼)的董事会成员,该基金是美国领先的Heathcare REIT旗舰医疗保健Properties Fund的独立投资组合。此前,Kevin曾担任Credit Agricole/Amundi Asset Management的高级投资组合经理,直到2015年10月,也曾担任摩根士丹利的资产配置董事(从2004年8月到2008年8月),以及中国开发银行的经理(从1998年9月到2000年8月)。Kevin是中国绝对回报投资管理协会联席Founder兼副主席。Kevin也是哈佛大学、福特汉姆大学、佩斯大学和IESE商学院的特邀演讲人。他是纽约大学全球事务理学硕士私人部门集中项目的前兼职咨询委员会成员和前临时负责人,自2012年以来一直是该公司的兼职教授。他是纽约经济俱乐部的成员,纽约金融论坛的联合主席,外交政策协会的研究员,布雷顿森林委员会的成员,科罗拉多大学丹佛商学院摩根大通大宗商品中心全球大宗商品应用研究文摘编辑顾问委员会成员。Kevin于2005年在瑞士洛桑大学金融资产管理工程中心获得金融学博士学位,于2001年在荷兰蒂尔堡大学经济研究中心获得金融学硕士学位,并于1998年在中国人民大学获得经济学学士学位。
Kevin Chen,has been Edoc Acquisition Corp. Chairman of the board of directors and Chief Executive Officer since September 2020. Mr. Chen has been serving as Chief Investment Officer and Chief Economist of Horizon Financial, a New York based investment management company that offers cross-border investment solutions to global financial institutions and individuals, since May 2018, where he is responsible for advising clients in investing healthcare facilities in the United States. Since November 2021, Mr. Chen has been a board member of InFinT Acquisition Corporation (NYSE: IFIN.U), a special purpose acquisition company that completed its initial public offering in November 23, 2021. Mr. Chen has also been serving as a board member of Horizon Global Access Fund (Cayman), a segregate portfolio of Flagship Healthcare Properties Fund, a leading U.S. Healthcare REIT, since February 2019. Previously Kevin served as a senior portfolio manager of Credit Agricole/Amundi Asset Management until October 2015, a director of Asset Allocation of Morgan Stanley from August 2004 to August 2008, and a manager of China Development Bank from September 1998 to August 2000. Kevin is Co-Founder and Vice-Chairman of the Absolute Return Investment Management Association of China. Kevin has also been a guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. He is a former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program of Master of Science in Global Affairs, New York University, and has been an adjunct professor there since 2012. He is a Member of the Economic Club of New York, Fellow of the Foreign Policy Association, Member of the Bretton Woods Committee, Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Kevin obtained his PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland in 2005, Master's degree in Finance, Center for Economic Research, Tilburg University in the Netherland in 2001, and B.A. degree in Economics from the Renmin University of China in China in 1998.- 陈凯文自2020年9月以来一直担任我们的董事会主席兼首席执行官。陈天桥一直担任Horizon Financial的首席投资官和首席经济学家,Horizon Financial是一家总部位于纽约的投资管理公司,为全球金融机构和个人提供跨境投资解决方案,自2018年5月起,他负责建议客户在美国投资医疗保健设施。自2021年11月以来,陈先生一直是Infint Acquisition Corporation的董事会成员,NYSE:IFIN.U是一家特殊目的收购公司,于2021年11月23日完成了首次公开募股。自2019年2月以来,陈先生还一直担任Horizon Global Access Fund(开曼)的董事会成员,该基金是美国领先的Heathcare REIT旗舰医疗保健Properties Fund的独立投资组合。此前,Kevin曾担任Credit Agricole/Amundi Asset Management的高级投资组合经理,直到2015年10月,也曾担任摩根士丹利的资产配置董事(从2004年8月到2008年8月),以及中国开发银行的经理(从1998年9月到2000年8月)。Kevin是中国绝对回报投资管理协会联席Founder兼副主席。Kevin也是哈佛大学、福特汉姆大学、佩斯大学和IESE商学院的特邀演讲人。他是纽约大学全球事务理学硕士私人部门集中项目的前兼职咨询委员会成员和前临时负责人,自2012年以来一直是该公司的兼职教授。他是纽约经济俱乐部的成员,纽约金融论坛的联合主席,外交政策协会的研究员,布雷顿森林委员会的成员,科罗拉多大学丹佛商学院摩根大通大宗商品中心全球大宗商品应用研究文摘编辑顾问委员会成员。Kevin于2005年在瑞士洛桑大学金融资产管理工程中心获得金融学博士学位,于2001年在荷兰蒂尔堡大学经济研究中心获得金融学硕士学位,并于1998年在中国人民大学获得经济学学士学位。
- Kevin Chen,has been Edoc Acquisition Corp. Chairman of the board of directors and Chief Executive Officer since September 2020. Mr. Chen has been serving as Chief Investment Officer and Chief Economist of Horizon Financial, a New York based investment management company that offers cross-border investment solutions to global financial institutions and individuals, since May 2018, where he is responsible for advising clients in investing healthcare facilities in the United States. Since November 2021, Mr. Chen has been a board member of InFinT Acquisition Corporation (NYSE: IFIN.U), a special purpose acquisition company that completed its initial public offering in November 23, 2021. Mr. Chen has also been serving as a board member of Horizon Global Access Fund (Cayman), a segregate portfolio of Flagship Healthcare Properties Fund, a leading U.S. Healthcare REIT, since February 2019. Previously Kevin served as a senior portfolio manager of Credit Agricole/Amundi Asset Management until October 2015, a director of Asset Allocation of Morgan Stanley from August 2004 to August 2008, and a manager of China Development Bank from September 1998 to August 2000. Kevin is Co-Founder and Vice-Chairman of the Absolute Return Investment Management Association of China. Kevin has also been a guest speaker at Harvard University, Fordham University, Pace University, and IESE Business School. He is a former member of the Adjunct Advisory Committee and former Interim Head of the Private Sector Concentration program of Master of Science in Global Affairs, New York University, and has been an adjunct professor there since 2012. He is a Member of the Economic Club of New York, Fellow of the Foreign Policy Association, Member of the Bretton Woods Committee, Editorial Advisory Board Member of the Global Commodity Applied Research Digest (GCARD) at JP Morgan Center for Commodities (JPMCC) at the University of Colorado Denver Business School. Kevin obtained his PhD in Finance from the Financial Asset Management Engineering Center at University of Lausanne, Switzerland in 2005, Master's degree in Finance, Center for Economic Research, Tilburg University in the Netherland in 2001, and B.A. degree in Economics from the Renmin University of China in China in 1998.
- Bob Ai
Bob Ai,2011年2月,被任命为首席财务官办公室成员。他有着10年多的华尔街工作经验,以及15年的科学研究学术经验。最近的任职是在2007-2011,担任Merlin Nexus的合伙人,负责投资决策和分析和评估,这是投资于生命科学公司的私募股权公司。2006-2007,他担任经纪交易商Wall Street Access的副总裁,负责行业研究;2004-2005,担任资产管理公司Bennett Lawrence的高级股票分析师;2001-2004,担任资产管理公司Merlin Biomed的分析师。进入金融行业之前,他在University of Pennsylvania担任了7年的研究助理、博士后研究学者。2001年,他在 Penn State University 获得工商管理硕士学位;1992年,在该校获得分子与细胞生物博士学位。
Bob Ai,has served as a Director since November 2020 and as Edoc Acquisition Corp. Chief Financial Oficcer since October 2022. Mr. Ai has served as a managing partner of Goby Global LLC, which provides financial communications, cross-border licensing, and other strategic advisory services since January 2022. From September 2016 to December 2021, Mr. Ai served as managing director of Solebury Trout, a strategic communications firm. Prior to this, Mr. Ai served as a Managing Director and a Senior Biotech Analyst of WallachBeth Capital, a boutique broker-dealer. From February 2011 to June 2012, he served as Chief Financial Officer of Aoxing Pharmaceutical, an NYSE-listed Chinese specialty pharmaceutical company at the time. He also served as a Principal of Merlin Nexus, a crossover life science private equity firm, from March 2007 to January 2011, and served as a Senior Equity Analyst of Bennett Lawrence and Merlin Biomed Group, both asset management firms. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses, which are currently inactive. Mr. Ai received his Ph.D. and MBA degrees from Penn State University in 1992 and 2001, respectively, and did postdoctoral training at the University of Pennsylvania.- Bob Ai,2011年2月,被任命为首席财务官办公室成员。他有着10年多的华尔街工作经验,以及15年的科学研究学术经验。最近的任职是在2007-2011,担任Merlin Nexus的合伙人,负责投资决策和分析和评估,这是投资于生命科学公司的私募股权公司。2006-2007,他担任经纪交易商Wall Street Access的副总裁,负责行业研究;2004-2005,担任资产管理公司Bennett Lawrence的高级股票分析师;2001-2004,担任资产管理公司Merlin Biomed的分析师。进入金融行业之前,他在University of Pennsylvania担任了7年的研究助理、博士后研究学者。2001年,他在 Penn State University 获得工商管理硕士学位;1992年,在该校获得分子与细胞生物博士学位。
- Bob Ai,has served as a Director since November 2020 and as Edoc Acquisition Corp. Chief Financial Oficcer since October 2022. Mr. Ai has served as a managing partner of Goby Global LLC, which provides financial communications, cross-border licensing, and other strategic advisory services since January 2022. From September 2016 to December 2021, Mr. Ai served as managing director of Solebury Trout, a strategic communications firm. Prior to this, Mr. Ai served as a Managing Director and a Senior Biotech Analyst of WallachBeth Capital, a boutique broker-dealer. From February 2011 to June 2012, he served as Chief Financial Officer of Aoxing Pharmaceutical, an NYSE-listed Chinese specialty pharmaceutical company at the time. He also served as a Principal of Merlin Nexus, a crossover life science private equity firm, from March 2007 to January 2011, and served as a Senior Equity Analyst of Bennett Lawrence and Merlin Biomed Group, both asset management firms. He has published eight articles in peer-reviewed scientific journals and also won the prestigious Ray Wu scholarship for outstanding Chinese student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses, which are currently inactive. Mr. Ai received his Ph.D. and MBA degrees from Penn State University in 1992 and 2001, respectively, and did postdoctoral training at the University of Pennsylvania.